AstraZeneca-partnered RNA player Silence plans Nasdaq listing

Silence Therapeutics has outlined plans to list its stock on Nasdaq, giving it access to U.S. investors to support the progress of its internal and AstraZeneca-partnered RNA therapeutics.

London-based Silence has traded on the stock exchange in its home city since the 1990s, when it was called Stanford Rook Holdings and focused on an immunotherapy treatment for tuberculosis. The modern version of Silence emerged around a decade later, after late-phase failures while called Stanford and SR Pharma led the biotech to pivot to RNA by acquiring Atugen and Intradigm.